For example, introducing an SDF-1α (CXCL-12) inhibitor to anti-VEGF antibodies significantly reduced the level of TAMs and prolonged the survival time of glioblastoma-bearing rodents compared with the VEGF blockade alone [116]. The gene discussed is CXCL12; the disease is glioblastoma.